Second chance: new combo aims to clear hepatitis c after relapse
NCT ID NCT07565948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Researchers will also monitor liver function and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sofosbuvir/Velpatasvir/Voxilaprevir (a combination of three antiviral drugs)
What this could lead to
If successful, this could provide a reliable retreatment option for hepatitis C patients whose virus came back after initial therapy.
What could go wrong
This is a mid-stage study with 200 participants, so results may not apply to everyone. Some patients may not respond or may experience side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C VIRUS (HCV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410000, China